A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Servier
Servier
Seagen Inc.
Qurient Co., Ltd.
Nouscom SRL
Rutgers, The State University of New Jersey
ImmunityBio, Inc.
Amgen
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astellas Pharma Inc
Toray Industries, Inc
University of Colorado, Denver
Carisma Therapeutics Inc
NextCure, Inc.
National Cancer Center Hospital East
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
University of Kansas Medical Center